MX2021005910A - Formulacion de proteina de alta concentracion. - Google Patents

Formulacion de proteina de alta concentracion.

Info

Publication number
MX2021005910A
MX2021005910A MX2021005910A MX2021005910A MX2021005910A MX 2021005910 A MX2021005910 A MX 2021005910A MX 2021005910 A MX2021005910 A MX 2021005910A MX 2021005910 A MX2021005910 A MX 2021005910A MX 2021005910 A MX2021005910 A MX 2021005910A
Authority
MX
Mexico
Prior art keywords
high concentration
protein formulation
concentration protein
formulation
compositions
Prior art date
Application number
MX2021005910A
Other languages
English (en)
Inventor
Hunter Chen
Erica Schlesinger
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021005910A publication Critical patent/MX2021005910A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Abstract

La presente invención se refiere a composiciones y métodos para preparar formulaciones de proteínas de alta concentración de una proteína terapéutica.
MX2021005910A 2018-11-21 2019-11-21 Formulacion de proteina de alta concentracion. MX2021005910A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770337P 2018-11-21 2018-11-21
PCT/US2019/062596 WO2020106948A1 (en) 2018-11-21 2019-11-21 High concentration protein formulation

Publications (1)

Publication Number Publication Date
MX2021005910A true MX2021005910A (es) 2021-08-16

Family

ID=68916589

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005910A MX2021005910A (es) 2018-11-21 2019-11-21 Formulacion de proteina de alta concentracion.

Country Status (13)

Country Link
US (1) US20200155678A1 (es)
EP (1) EP3883542A1 (es)
JP (1) JP2022532965A (es)
KR (1) KR20210093976A (es)
CN (1) CN113164378A (es)
AU (1) AU2019384160A1 (es)
BR (1) BR112021009463A2 (es)
CA (1) CA3118306A1 (es)
EA (1) EA202191403A1 (es)
IL (1) IL283229A (es)
MX (1) MX2021005910A (es)
SG (1) SG11202104166QA (es)
WO (1) WO2020106948A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
UA128098C2 (uk) 2019-02-18 2024-04-03 Елі Ліллі Енд Компані Водна фармацевтична композиція антитіла проти il-17a

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US9072668B2 (en) * 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
EP2683362A4 (en) * 2011-03-10 2014-09-17 Univ Texas DISPERSIONS OF NANOPARTICLES OF PROTEINS
CN103356490A (zh) * 2012-03-29 2013-10-23 复旦大学 可直接固体化的交联食物蛋白稳定化纳米给药系统
EP2849723B1 (en) * 2012-05-18 2018-05-02 Genentech, Inc. High-concentration monoclonal antibody formulations
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EP3808338A1 (en) * 2013-09-11 2021-04-21 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids
LT2942050T (lt) * 2014-05-06 2023-01-10 S.I.I.T. S.R.L.-Servizio Internazionale Imballaggi Termosaldanti Purškiama aliejinga kompozicija riebaluose tirpių d grupės vitaminų pagrindu, ir jos panaudojimas
EP3240571A4 (en) * 2014-12-31 2018-06-13 NovelMed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies

Also Published As

Publication number Publication date
WO2020106948A1 (en) 2020-05-28
BR112021009463A2 (pt) 2021-08-10
CA3118306A1 (en) 2020-05-28
CN113164378A (zh) 2021-07-23
AU2019384160A1 (en) 2021-05-27
SG11202104166QA (en) 2021-05-28
US20200155678A1 (en) 2020-05-21
EA202191403A1 (ru) 2021-08-09
KR20210093976A (ko) 2021-07-28
IL283229A (en) 2021-07-29
JP2022532965A (ja) 2022-07-21
EP3883542A1 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
CL2018003582A1 (es) Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567)
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
MX2018014154A (es) Polinucleotidos moduladores.
MX2017001279A (es) Usos y composiciones de la flagelina.
MX2019015018A (es) Composiciones que comprenden curones y usos de los mismos.
MX2019012978A (es) Composiciones para el cuidado bucal y metodos para utilizar las composiciones.
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
MX2020001885A (es) Formulaciones de daptomicina.
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
MX2019014772A (es) Formulaciones en gel de bisfosfocinas y usos de estas.
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX2022014457A (es) Formulaciones de inmunoconjugado anti-cd79b estables.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
MX2019005925A (es) Composiciones de alergenos liquidas y metodos para la preparacion de las mismas.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
MX2019011613A (es) Formulaciones de acido 1-amino-1-ciclopropanocarboxilico.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2021005910A (es) Formulacion de proteina de alta concentracion.
MX2021016050A (es) Formulaciones transdermicas.
MX2021006977A (es) Anellosomas y metodos de uso.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.